Precision Biosciences (DTIL) Current Assets (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Current Assets data on file, last reported at $108.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $108.7 million, up 32.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $108.7 million (up 32.39% YoY), and the FY2025 annual result was $118.7 million, up 25.0% from the prior year.
• Current Assets fell to $108.7 million in Q1 2026 per DTIL's latest filing, from $118.7 million in the prior quarter.
• Over five years, Current Assets peaked at $247.7 million in Q2 2022 and troughed at $51.7 million in Q3 2025.
• A 5-year average of $138.1 million and a median of $136.4 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2025 and 2026: Current Assets tumbled 53.22% in 2025, then jumped 32.39% in 2026.
• A 5-year view of Current Assets shows it stood at $199.1 million in 2022, then slumped by 31.51% to $136.4 million in 2023, then tumbled by 30.34% to $95.0 million in 2024, then grew by 25.0% to $118.7 million in 2025, then decreased by 8.46% to $108.7 million in 2026.
• Business Quant data shows DTIL's Current Assets at $108.7 million in Q1 2026, $118.7 million in Q4 2025, and $51.7 million in Q3 2025.